KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Gross Profit (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Gross Profit data on record, last reported at $3.7 billion in Q4 2025.

  • For Q4 2025, Gross Profit changed N/A year-over-year to $3.7 billion; the TTM value through Dec 2025 reached $13.4 billion, changed N/A, while the annual FY2025 figure was $13.4 billion, 2.05% up from the prior year.
  • Gross Profit reached $3.7 billion in Q4 2025 per REGN's latest filing, up from $3.5 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $8.3 billion in Q3 2021 and bottomed at -$157.3 million in Q1 2022.
  • Average Gross Profit over 5 years is $2.8 billion, with a median of $2.9 billion recorded in 2023.
  • Peak YoY movement for Gross Profit: tumbled 106.71% in 2022, then skyrocketed 1951.88% in 2023.
  • A 5-year view of Gross Profit shows it stood at $8.3 billion in 2021, then plummeted by 96.36% to $301.0 million in 2022, then soared by 942.59% to $3.1 billion in 2023, then rose by 10.2% to $3.5 billion in 2024, then grew by 8.33% to $3.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $3.7 billion in Q4 2025, $3.5 billion in Q3 2025, and $3.4 billion in Q2 2025.